

CITATION REPORT

List of articles citing

The CA 125 tumour-associated antigen: a review of the literat

DOI: 10.1093/oxfordjournals.humrep.a136832
Human Reproduction, 1989, 4, 1-12.

Source: <https://exaly.com/paper-pdf/20954690/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
588	Serum CA-125 levels do not depend on ovarian steroidogenesis. 1990 , 54, 415-8		25
587	Occurrence of the mucinous differentiation antigen CA125 in genital tract and conductive airway epithelia of diverse mammalian species (rabbit, dog, monkey). 1990 , 45, 192-8		19
586	Production of various marker substances in human ovarian cancer cell lines of epithelial origin. 1990 , 248, 103-10		5
585	Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms. 1990 , 76, 505-510		2
584	The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. 1990 , 163, 1164-7		41
583	Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer. 1990 , 37, 265-70		4
582	Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. 1990 , 33, 149-52		13
581	CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. 1990 , 36, 161-5		27
580	Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum. 1990 , 163, 1276-81		13
579	News. 1991 , 27, 663-666		
578	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. 1991 , 165, 1356-1362		50
577	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. 1991 , 165, 1356-62		62
576	Ovarian cancer screening. 1991 , 27, 655-9		21
575	Coordinate elevation of serum markers in ovarian cancer but not in benign disease. 1991 , 68, 1758-63		52
574	Abstracts. 1991 , 9, 343-399		3
573	CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. 1992 , 52, 201-6		30
572	What do CA 125 and other antigens tell us about ovarian cancer biology?. 1992 , 155, 85-93		11

571	Unsettled questions regarding ovarian cancer. 1992 , 155, 7-18	3
570	CA-125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis**Presented in part at the 7th World Congress on Human Reproduction, Helsinki, Finland, June 26, 1990.¶Supported by grant 9.0020.90 from the Belgian Fonds voor Wetenschappelijk Onderzoek, Brussels, Belgium, and by grants from the Academy of	103
569	CA-125 levels in human uterine fluid**Presented in part at the 46th Annual Meeting of The American Fertility Society, Washington, D.C., October 13 to 18, 1990.. 1992 , 57, 531-534	13
568	Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. 1992 , 28A, 2002-6	19
567	Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. 1992 , 47, 245-52	8
566	Tumour markers for ovarian cancer. 1992 , 28, 2-3	57
565	Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. 1992 , 28A, 1695-702	54
564	The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. 1992 , 44, 147-54	98
563	The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. 1992 , 44, 155-60	35
562	False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation. 1992 , 47, 127-9	2
561	The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. 1992 , 46, 29-32	12
560	Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma. 1992 , 45, 279-83	3
559	CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. 1992 , 45, 323-8	14
558	Early Diagnosis and Screening. 1992 , 6, 843-850	5
557	Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. 1992 , 35, 19-26	25
556	An overview of screening and early detection of gynecologic malignancies. 1993 , 71, 1400-5	2
555	Ovarian cancer screening. 1993 , 71, 1523-8	24
554	Serum CA 125 levels in patients with non-malignant liver diseases without ascites. 1993 , 71, 239	2

553	The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. 1993 , 67, 1065-70	4
552	An epidemiologic perspective on biomarkers. 1993 , 233, 75-9	17
551	Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity. 1993 , 16, 175-9	10
550	Highly elevated serum CA 125 levels in a patient with cardiac failure. 1993 , 48, 71-3	10
549	Laparoscopic ovarian surgery. Panel discussion at the 21st annual meeting of the American Association of Gynecologic Laparoscopists (AAGL). September 25, 1992. 1993 , 1, 78-84	3
548	What do we know about the origin of CA 125?. 1993 , 49, 93-8	62
547	Discordant serum CA 125 values in commercial immunoassays. 1993 , 49, 99-103	14
546	CA 125 in the management of endometriosis. 1993 , 49, 109-13	18
545	CA 125 in gynecological pathology--a review. 1993 , 49, 115-24	71
544	Screening for ovarian cancer. Uptake of screening would be low. 1993 , 306, 1685-6	1
543	Appendectomy in children. Retrospective audit won't give the answer. 1993 , 306, 1686; author reply 1687	
542	Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. 1993 , 306, 1030-4	268
541	CA 125 half-life in ovarian cancer: a multivariate survival analysis. 1993 , 67, 1361-7	44
540	The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. 1993 , 68, 140-5	20
539	Screening for ovarian cancer: Authors' reply. 1993 , 306, 1685-1686	
538	Follicular fluid alpha-fetoprotein, carcinoembryonic antigen, and CA-125 levels in relation to in vitro fertilization and gonadotropin and steroid hormone concentrations. 1993 , 59, 1257-60	13
537	The management of ovarian cancer. 1993 , 4, 883-7	
536	Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. 1993 , 306, 1684-5	3

- 535 Appendicectomy in children. No time for daytime emergencies. **1993**, 306, 1686-7
- 534 Should we regard CA125 as the indication to treat relapsing ovarian cancer?. **1993**, 4, 257
- 533 Screening for ovarian cancer. Other malignancies cloud the issue. **1993**, 306, 1685 2
- 532 Appendicectomy in children. No excuse for unnecessary delays. **1993**, 306, 1686; author reply 1687 1
- 531 Appendicectomy in children. Unconvincing message. **1993**, 306, 1686; author reply 1687
- 530 Relation between Ovarian Carcinoma-Associated Antigens in Tumor Tissue and Detached Cyst Fluid Cells of Patients with Ovarian Neoplasms. **1994**, 80, 50-55 7
- 529 The role of ultrasound and tumour markers in the early detection of ovarian cancer. **1994**, 101, 939-45 6
- 528 Tumour-associated antigens, CEA, CA 125 and SCC in serum and follicular fluid of stimulated and unstimulated cycles. **1994**, 54, 131-6 12
- 527 Ovarian carcinoma: early detection and screening. **1994**, 4, 2-6
- 526 Biological markers and ovarian carcinomas: galactosyltransferase, CA 125, isoenzymes of amylase and alkaline phosphatase. **1994**, 227, 87-96 9
- 525 Performances analytiques d'un nouvel automate d'immunoanalyse : le LIA-mat S300. **1994**, 9, 181-187
- 524 Screening for ovarian cancer: the role of noninvasive imaging techniques. **1994**, 170, 1088-94 27
- 523 Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. **1994**, 171, 1183-91 9
- 522 Adenocarcinoma of the submandibular gland with positive serum and tissue immunohistochemical staining for both CEA and CA 125: report of a case. **1994**, 108, 719-21
- 521 Detection of a unique 32-kd protein in the peritoneal fluid of women with endometriosis*†Supported in part by grant HD21962 from the National Institutes of Health, Bethesda, Maryland.†Presented in part at the 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, October 30 to November 5, 1992.. **1994**, 61, 288-293 14
- 520 CA-125 levels in cervical mucus during the menstrual cycle. **1994**, 61, 843-9 10
- 519 CA125 Serum levels in tuberculosis patients. **1995**, 10, 180-181 3
- 518 Inhibin as a marker for ovarian cancer. **1995**, 71, 1046-50 93

517	Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis*† Presented in part at the International Meeting: CA-125 Ten Years Later, San Remo, Italy, October 10 to 13, 1993, and at the 50th annual meeting of The American Fertility Society, San Antonio, Texas, November 7 to 10, 1994. ‡ Supported in part by a grant from Abbott Laboratories, Abbott Park, Illinois. 1995 , 64, 321-324	33
516	Elevated serum CA125 in progressive systemic sclerosis with pleural effusion. 1995 , 22, 28-31	23
515	Clinical validation of the new ELSA-CA 125 II assay: report of a European multicentre evaluation. 1995 , 60, 199-203	6
514	Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. 1995 , 12, 263-8	7
513	CA 72-4 serum marker--a new tool in the management of carcinoma patients. 1995 , 13, 227-38	37
512	Trans-vaginal ultrasound examination of ovarian masses in premenopausal women. 1995 , 62, 37-41	12
511	Correlations between periovulatory serum and follicular fluid CA-125 and granulosa cell hormones after controlled ovarian hyperstimulation. 1995 , 62, 95-9	2
510	Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. 1995 , 173, 112-9	32
509	Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. 1995 , 173, 558-65	48
508	Screening and early diagnosis of gynecologic cancers. 1996 , 80, 45-61	4
507	PET and [18F]-FDG in oncology: a clinical update. 1996 , 23, 717-35	220
506	Maternal serum CA 125 is of prognostic value in patients with uterine bleeding in the detection of small-for-gestational-age neonates. 1996 , 67, 143-7	3
505	Pelvic masses and endoscopic surgery: diagnosis. 1996 , 65, 75-9	1
504	CA 125: a misleading tumor marker?. 1996 , 55, 179-80	3
503	Comparison of One First-Generation and Three Second-Generation Methods for the Determination of CA 125. 1996 , 11, 36-39	
502	Altered expression of CA-125 in breast carcinomas. 1996 , 104, 47-53	3
501	Colonic adenocarcinoma in a rhesus macaque (<i>Macaca mulatta</i>). 1996 , 25, 435-8	6
500	Evaluations and Validations. 1997 , 35,	

499	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. 1997 , 18, 435-61	100
498	Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. 1997 , 65, 241-4	29
497	Pelvic hematoma following angiography: another cause of elevated serum CA-125. 1997 , 65, 370-2	5
496	Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. 1997 , 65, 512-6	40
495	Immunocytochemical localization of Cathepsin D and CA 125 in ovarian cancer. 1997 , 56, 31-7	3
494	Transvaginal color Doppler and CA125 as tools in the differential diagnosis of postmenopausal ovarian masses. 1997 , 26, 203-9	6
493	Tumor Markers in Ovarian Malignancies. 1997 , 2, 324-329	27
492	The pituitary-gonadal function in postmenopausal women with epithelial ovarian tumors. 1997 , 105, 5-27	
491	Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. 1997 , 18, 251-70	52
490	Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. 1997 , 7, 78-83	13
489	Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients. 1997 , 11, 94-103	2
488	Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. 1998 , 69, 56-63	34
487	The performance of screening tests for ovarian cancer: results of a systematic review. 1998 , 105, 1136-47	91
486	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. 1998 , 77, 1870-4	52
485	Primary ovarian angiosarcoma: a case report and literature review. 1998 , 48, 967-73	17
484	Clinical utility of CA125 levels in predicting laparoscopically confirmed salpingitis in patients with clinically diagnosed pelvic inflammatory disease. 1998 , 6, 182-5	7
483	Metaplastic changes in cultured human ovarian surface epithelium. 1998 , 34, 668-70	14
482	Ovarian cancer complicating pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 1998 , 25, 385-99	3-3 98

481	Granulosa cell tumours of the ovary express inhibin but not CA125. 1998 , 18, 355-8		1
480	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1998. A 31-year-old woman with a pleural effusion, ascites, and persistent fever spikes. 1998 , 338, 248-54		17
479	CA 125: The past and the Future. 1998 , 13, 179-187		287
478	More than 15 Years of CA 125: What is Known about the Antigen, Its Structure and Its Function. 1998 , 13, 188-195		55
477	CA 125 Production and Release by Ovarian Cancer Cells In Vitro. 1998 , 13, 200-206		19
476	Il Carcinoma Dell'ovaio Avanzato Stato Dell'arte e Prospettive Future. 1998 , 84, A1-A22		
475	Tissue Quantification of CA 125 in Epithelial Ovarian Cancer. 1999 , 14, 106-114		15
474	Serum CA-125 values on the day of oocyte retrieval are not predictive of subsequent pregnancy with in-vitro fertilization. <i>Human Reproduction</i> , 1999 , 14, 1773-6	5-7	11
473	Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. 1999 , 96, 11531-6		258
472	Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. 1999 , 73, 56-61		64
471	Increased mortality in postmenopausal women with serum CA125 elevation. 1999 , 73, 242-6		5
470	A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. 1999 , 181, 57-65		127
469	Molecular methods for the diagnosis of cancer. 1999 , 1423, C11-8		10
468	Is there a place for screening in ovarian cancer?. 1999 , 82, 155-7		8
467	Expression of mucins and cytokeratins in ovarian cancer cell lines. 1999 , 145, 133-41		24
466	Screening for gynecologic cancer. 1999 , 83, 1467-87		5
465	Screening for ovarian cancer. We now need a definitive randomised trial. 1999 , 319, 1317-8		13
464	Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour. 2000 , 36, 109-15		67

463	Tuberculous peritonitis: part of the differential diagnosis in ovarian cancer. 2000 , 182, 740-2	46
462	Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. 2000 , 21, 2735-309S	704
461	Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. 2000 , 77, 454-9	115
460	Tumour markers and ovarian cancer screening. 2000 , 2, 41-44	0
459	Prognostic Value of CA125 Kinetics and Half-Life in Advanced Ovarian Cancer. 2000 , 15, 147-152	32
458	Human First Trimester Fetal Ovaries Express Oncofetal Antigens and Steroid Receptors. 2000 , 7, 131-138	5
457	Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. 2000 , 165, 1705-11	200
456	An application of artificial neural networks in ovarian cancer early detection. 2000 ,	3
455	A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement. 2000 , 120, 268-70	8
454	Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. 2000 , 53, 327-34	61
453	How CA 125 is used in routine clinical practice. 2000 , 36, 1933-7	15
452	Elevated serum CA 125 and adnexal mass mimicking ovarian carcinoma in a patient with tuberculous peritonitis. 2001 , 8, 110-115	1
451	Caracterizaci3n preoperatoria de las tumoraciones de ovario mediante ecograf3a, Doppler y determinaci3n s3rica de CA125. Estudio comparativo. 2001 , 44, 205-215	
450	Ovarian surface epithelium: biology, endocrinology, and pathology. 2001 , 22, 255-88	778
449	Dialysate Cancer Antigen 125 Concentration as Marker of Peritoneal Membrane Status in Patients Treated with Chronic Peritoneal Dialysis. 2001 , 21, 560-567	95
448	Serum Tumor Markers: Past, State of the Art, and Future. 2001 , 16, 73-86	22
447	The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. 2001 , 20, 155-9	59
446	Application of tumor markers in ovarian malignancies. 2001 , 16, 224-33	5

445	Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma. 2001 , 38, 542-9	4
444	Lysophosphatidic acid and ovarian cancer: a paradigm for tumorigenesis and patient management. 2001 , 64, 63-81	21
443	Screening for the major malignancies affecting women: current guidelines. 2001 , 184, 1021-30	34
442	The haemodialysis patient with night sweats, ascites, and increased CA 125. 2001 , 16, 175-7	2
441	Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. 2002 , 78, 733-9	82
440	Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma. 2002 , 84, 413-5	3
439	Expression and clinical significance of pepsinogen C in epithelial ovarian carcinomas. 2002 , 104, 58-63	10
438	The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. 2002 , 187, 385-92	28
437	Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. 2002 , 95, 1886-93	58
436	Use of CA-125 and ultrasound in high-risk women. 2002 , 12, 86-91	35
435	Gene expression in epithelial ovarian carcinoma. 2002 , 21, 6289-98	83
434	Specific keynote: ovarian cancer risk assessment and the potential for early detection. 2003 , 88, S75-9; discussion S80-3	16
433	Tuberculous peritonitis mimicking peritonitis carcinomatosis: a case report. 2003 , 162, 853-5	15
432	Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. 2003 , 91, 15-31	52
431	Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. 2003 , 98, 66-73	96
430	Inhibins and activins: clinical advances in reproductive medicine. 2003 , 58, 115-27	24
429	[Clinical utility of serous tumoural markers]. 2003 , 32, 227-39	2
428	Ovarian cancer screening. 2003 , 17, 989-1005, ix	47

427	Molecular markers for early detection of renal carcinoma: investigative approach. 2004 , 10, 6296S-301S		21
426	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. 2004 , 64, 5882-90		796
425	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. 2004 , 10, 3919-26		106
424	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. 2004 , 93, 131-6		37
423	The use of mathematical models to evaluate pelvic masses; can they beat an expert operator?. 2004 , 18, 91-104		72
422	Ovarian Carcinogenesis. 2004 , 591-612		5
421	Laparoscopic management of ovarian cysts. <i>Obstetrics and Gynecology Clinics of North America</i> , 2004 , 31, 581-92, ix	3-3	10
420	Serum tumor markers in the management of ovarian, endometrial and cervical cancer. 2004 , 58, 24-38		133
419	Laparoscopic Management of Adnexal Masses. 2004 , 60, 28-30		4
418	Analysis of molecular aberrations in ovarian cancer allows novel target identification. 2004 , 26, 461-74		1
417	Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. 2005 , 193, 568-74; discussion 574-6		24
416	Management of adnexal masses in postmenopausal women. 2005 , 193, 30-5		30
415	Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. 2005 , 96, 516-9		49
414	Potential markers that complement expression of CA125 in epithelial ovarian cancer. 2005 , 99, 267-77		279
413	Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. 2005 , 99, 462-71		32
412	Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. 2005 , 14, 981-7		220
411	Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. 2005 , 14, 306-18		47
410	Immunohistochemical Validation of B7-H4 (DD-O110) as a Biomarker of Ovarian Cancer: Correlation with CA-125. 2005 , 4, 499-503		

409	Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. 2005 , 14, 1717-23	53
408	Tumor necrosis factor-alpha-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites. 2005 , 51, 2207-8	8
407	Do levels of serum cancer antigen 125 and creatine kinase predict the outcome in pregnancies of unknown location?. <i>Human Reproduction</i> , 2005 , 20, 3348-54	5:7 32
406	[CA125 cytosolic levels in lung adenocarcinomas. New biological aspects]. 2005 , 24, 27-31	
405	The development of a mouse model of ovarian endosalpingiosis. 2005 , 146, 5228-36	45
404	Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. 2006 , 5, 1626-35	194
403	The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. 2006 , 32, 588-91	15
402	Ovarian Cancer Screening. 47-68	0
401	Laparoscopic management of the adnexal mass. 2006 , 49, 535-48	49
400	The incidental postmenopausal adnexal mass. 2006 , 49, 506-16	47
399	Screening for ovarian cancer. 2006 , 49, 433-47	65
398	Diagnosis and management of epithelial ovarian cancer. 2006 , 107, 1399-410	150
397	Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. 2000 , 905, 242-59	131
396	Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. 2006 , 100, 247-53	35
395	Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. 2006 , 102, 542-5	45
394	Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. 2006 , 1765, 189-222	119
393	Screening for ovarian cancer in the general population. 2006 , 20, 307-20	33
392	Evolving role of serum biomarkers in the management of ovarian cancer. 2006 , 2, 141-58	4

391	Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. 2006 , 66, 1792-8	31
390	Le dβistage du cancer ovarien. 2006 , 127-142	
389	Screening for ovarian cancer: progress and challenges. 2006 , 32, 173-5	
388	B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. 2006 , 66, 1570-5	144
387	Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. 2007 , 13, 4422-8	33
386	Common gynecologic problems in geriatric-aged women. 2007 , 50, 687-708	6
385	Update on ovarian cancer screening. 2007 , 19, 22-6	32
384	Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. 2007 , 38, 134-9	21
383	Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. 2007 , 17, 21-31	94
382	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. 2007 , 104, 508-15	90
381	Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. 2007 , 105, 395-8	14
380	Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. 2007 , 106, 112-8	90
379	Biochemical prognostic factors and risk of relapses in patients with cervical cancer. 2007 , 107, S23-6	28
378	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. 2007 , 107, 526-31	80
377	Microarray expression analysis of epithelial ovarian cancer with distinct differentiation . 2007 , 22, 373-375	
376	Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. 2007 , 17, 3223-35	74
375	The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. 2008 , 66, 10-20	109
374	Antigen-specific immunotherapy of cervical and ovarian cancer. 2008 , 222, 43-69	54

373	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. 2008 , 111, 179-87	32
372	Serum markers in the diagnosis of tubal pregnancy. 2008 , 63, 701-8	12
371	Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. 2008 , 140, 67-70	3
370	Early detection of ovarian cancer. <i>Biomarkers in Medicine</i> , 2008 , 2, 291-303	2.3 57
369	Proteomic contributions to personalized cancer care. 2008 , 7, 1780-94	77
368	Cancer antigen 125 and prognosis. 2008 , 20, 4-8	51
367	Surgery in Pregnancy. 393-454	
366	Ovarian cancer and masses. 187-192	
365	Gastrointestinal stromal tumor in pregnancy: a case report. 2009 , 2009, 456402	12
364	Menstrual changes: amenorrhea, oligomenorrhea, polycystic ovary syndrome, and abnormal menstrual bleeding. 129-136	
363	Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. 2009 , 8, 661-9	88
362	Meigs' Syndrome with Elevated Serum CA125: Case Report and Review of the Literature. 2009 , 2, 61-66	22
361	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. 2009 , 112, 462-8	109
360	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. 2009 , 112, 40-6	557
359	Urinary levels of Bcl-2 are elevated in ovarian cancer patients. 2009 , 112, 60-7	28
358	Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. 2009 , 113, 221-7	11
357	A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. 2009 , 115, 81-85	20
356	Genomic and proteomic biomarkers for cancer: a multitude of opportunities. 2009 , 1796, 176-93	48

355	Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. 2009 , 124, 919-23	100
354	The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. 2009 , 115, 1028-35	68
353	Mucins in ovarian cancer diagnosis and therapy. <i>Journal of Ovarian Research</i> , 2009 , 2, 21	5.5 40
352	Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. 2009 , 142, 99-105	84
351	Managing hereditary ovarian cancer. 2009 , 64, 172-6	16
350	Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?. 2009 , 16, 250-62	39
349	Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. 2009 , 2, 37	9
348	Oncology Biomarkers. 2009 ,	
347	Single conducting polymer nanowire chemiresistive label-free immunosensor for cancer biomarker. 2009 , 81, 2168-75	140
346	Differential methylation profile of ovarian cancer in tissues and plasma. 2009 , 11, 60-65	71
345	Predicting the response of advanced cervical and ovarian tumors to therapy. 2009 , 64, 548-60	15
344	Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. 2009 , 19, 1015-21	16
343	Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. 2010 , 20, 220-6	11
342	Identification of potential serum markers for endometrial cancer using protein expression profiling. 2010 , 136, 475-81	13
341	Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin?. 2010 , 1, 177-86	32
340	Pelvic mass associated with raised CA 125 for benign condition: a case report. 2010 , 8, 28	13
339	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. 2010 , 203, 228.e1-6	173
338	CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. 2010 , 116, 2850-3	46

337	Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. 1993 , 71, 582-8		77
336	A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. 1993 , 71, 589-93		96
335	Nidogen-2: a new serum biomarker for ovarian cancer. 2010 , 43, 355-61		26
334	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. 2010 , 103, 693-700		157
333	Ovarian cancer pathogenesis: a model in evolution. 2010 , 2010, 932371		168
332	Serum biomarkers for early detection of gynecologic cancers. <i>Cancers</i> , 2010 , 2, 1312-27	6.6	27
331	A step forward for two-step screening for ovarian cancer. 2010 , 28, 2128-30		12
330	Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. 2010 , 9, 1873-84		87
329	Apolipoprotein A1 and Transferrin as Biomarkers in Ovarian Cancer Diagnostics. 2010 , 10, 16-20		3
328	Ovarian cancer biomarker screening: still too early to tell. 2010 , 6, 487-90		9
327	Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. 2010 , 257, 144-50		53
326	Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. 2010 , 9, 1236-45		51
325	The Clinical Impact of Computed Tomography Immediately Following Primary Chemotherapy in Patients With Epithelial Ovarian Cancer. 2010 , 3, 52-55		
324	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. 2010 , 296, 43-8		71
323	Development of a multimarker assay for early detection of ovarian cancer. 2010 , 28, 2159-66		219
322	fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. 2011 , 5, 227-240		30
321	Prognostic biomarkers in ovarian cancer. 2010 , 8, 231-51		25
320	[Interest of CA 125 level in management of ovarian cancer]. 2011 , 39, 296-301		11

319	Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. 2011 , 158, 338-42	29
318	Meigs' syndrome with elevated serum cancer antigen 125 levels in a case of ovarian sclerosing stromal tumor. 2011 , 50, 196-200	25
317	Adding cancer antigen 125 screening to gray scale sonography for predicting specific diagnosis of benign adnexal masses in premenopausal women: is it worthwhile?. 2011 , 30, 1381-6	8
316	The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis. 2011 , 15, 625-32	7
315	A review of cost-effectiveness studies in ovarian cancer. 2011 , 18, 59-64	26
314	Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. 2011 , 117, 1289-1297	162
313	Comparison of candidate serologic markers for type I and type II ovarian cancer. 2011 , 122, 560-6	41
312	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. 2011 , 122, 548-53	61
311	Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. 2011 , 123, 295-300	36
310	Il carcinoma ovarico: nuove acquisizioni sulla patogenesi e nella diagnostica di laboratorio. 2011 , 7, 195-204	
309	Solid phase immunoradiometric assay for CA125 antigen levels in blood using monoclonal antibodies. 2011 , 288, 31-36	3
308	Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. 2011 , 60, 975-84	38
307	Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. 2011 , 32, 831-8	23
306	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. 2011 , 117, 545-53	24
305	Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. 2011 , 129, 1990-2001	37
304	ROMA or death: advances in epithelial ovarian cancer diagnosis. 2011 , 49, 443-5	5
303	Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. 2011 , 117, 1298-1306	61
302	A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study. 2011 , 20, 2420-8	23

301	Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. 2011 , 4, 1401-8		42
300	Risk of malignancy in sonographically confirmed ovarian tumors. 2012 , 55, 52-64		12
299	Cancer in Pregnancy. 2012 , 405-477.e9		
298	Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. 2012 , 21, 1902-12		67
297	Prise en charge des masses annexielles pendant la grossesse. 2012 , 7, 1-9		1
296	Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. 2012 , 22 Suppl 1, S24-6		49
295	Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. <i>Oncology Letters</i> , 2012 , 3, 66-74	2.6	7
294	Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. 2012 , 28, 585-91		12
293	HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. <i>Oncology Letters</i> , 2012 , 4, 385-389	2.6	14
292	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. 2012 , 33, 2117-23		51
291	N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. 2012 , 11, 2282-300		149
290	A urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection. 2012 , 12, 7423-37		23
289	Human epididymis protein 4 (HE4) in benign and malignant diseases. 2012 , 50, 2181-8		51
288	Protein biomarkers of ovarian cancer: the forest and the trees. 2012 , 8, 55-71		59
287	Diffuse peritoneal chlamydial infection presenting as possible ovarian peritoneal carcinomatosis in an adolescent female. 2012 , 50, 531-3		4
286	Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. 2012 , 48, 1649-56		90
285	Ruptured ovarian endometrioma with an extreme rise in serum CA 125 level - A case report: Ovarian endometrioma with very high CA-125 level. 2012 , 2, 100-1		3
284	Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. 2012 , 40, 245-54		13

283	Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. 2012 , 10, 45		13
282	Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. 2012 , 6, 360-9		91
281	Identification of quiescent, stem-like cells in the distal female reproductive tract. <i>PLoS ONE</i> , 2012 , 7, e40691	3-7	50
280	Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. 2012 , 11, 4541-52		80
279	Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. <i>PLoS ONE</i> , 2012 , 7, e44960	3-7	42
278	Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum. 2012 , 2012,		3
277	A comparison of the cyclic variation in serum levels of CA125 across the menstrual cycle using two commercial assays. 2012 , 14, 250-6		12
276	Health economics of screening for gynaecological cancers. 2012 , 26, 163-73		2
275	Screening for ovarian cancer in the general population. 2012 , 26, 243-56		36
274	Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. 2012 , 14, 123-9		34
273	The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. <i>Journal of Ovarian Research</i> , 2013 , 6, 45	5-5	41
272	Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT. 2013 , 47, 81-8		16
271	Surface Epithelial-Stromal Tumors of the OvaryOpen image in new window. 2013 , 107-248		1
270	Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. 2013 , 12, 4056-63		67
269	Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. 2013 , 12, 5383-94		86
268	Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. 2013 , 59, 1-21		24
267	Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2013 , 6, 79	5-5	9
266	Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. 2013 , 167, 81-5		58

265	Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. 2013 , 22, 1730-5		28
264	The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. 2013 , 128, 239-44		60
263	Tratamiento de las masas anexiales durante el embarazo. <i>EMC - Ginecología-Obstetricia</i> , 2013 , 49, 1-10	o	
262	Role of osteopontin in differential diagnosis of ovarian tumors. 2013 , 39, 1518-25		12
261	Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels. 2013 , 52, 185-91		9
260	Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. <i>PLoS ONE</i> , 2013 , 8, e60129	3.7	15
259	Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. 2013 , 12, 4046-55		45
258	What do we do with all the false-positive CA125s?. 2013 , 39, 160-2		
257	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. 2013 , 73, 874-889		34
256	High impact of FDG-PET/CT in diagnostic strategies for ovarian cancer. 2013 , 54, 340-8		15
255	What is new in gynecologic oncology? Thought-provoking articles from the past year. 2013 , 122, 393-394		
254	Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. 2013 , 122, 1114		2
253	Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. 2013 , 56, 234-41		9
252	Clinical significance of serum CA-125 in Korean females with ascites. 2013 , 54, 1241-7		5
251	Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer. <i>PLoS ONE</i> , 2013 , 8, e57084	3.7	43
250	Pretreatment CA 15-3 Levels do not Predict Disease-Free Survival in Patients with Advanced Epithelial Ovarian Cancer. 2013 , 99, 257-260		
249	Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification. 2014 , 21, e782-9		4
248	The expression of FAS-associated factor 1 and heat shock protein 70 in ovarian cancer. 2014 , 57, 281-90		12

247	Ovarian Cancer Biomarkers. 2014 , 25-77	19
246	Correlation of cytohistological expression and serum level of ca125 in ovarian neoplasm. 2014 , 8, 41-3	2
245	Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood. 2014 , 2, 18-23	9
244	The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases. 2014 , 2014, 238197	21
243	Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?. 2014 , 2014, 492537	2
242	Serum microRNAs in clear cell carcinoma of the ovary. 2014 , 53, 536-41	22
241	Risk-reducing surgery for women at high risk of epithelial ovarian cancer. 2014 , 16, 185-191	6
240	Mutational analysis of FOXL2 p.C134W and expression of bone morphogenetic protein 2 in Japanese patients with granulosa cell tumor of ovary. 2014 , 40, 1197-204	8
239	Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer. 2014 , 2014, 326593	11
238	Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. 2014 , 53, 30-4	11
237	Wnt/ β -catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. <i>Journal of Ovarian Research</i> , 2014 , 7, 16	5-5 57
236	HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. 2014 , 35, 7249-58	33
235	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. 2014 , 210, 78.e1-9	30
234	DNA methylation markers for early detection of women's cancer: promise and challenges. 2014 , 6, 311-27	61
233	Evaluation of biodegradable microspheres containing nomegestrol acetate in a rat model of endometriosis. 2014 , 65, 15-20	5
232	The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. 2014 , 211, 65.e1-65.e11	11
231	A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. 2014 , 132, 573-7	18
230	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. 2014 , 132, 560-5	39

229	In 2014, can we do better than CA125 in the early detection of ovarian cancer?. 2014 , 5, 286-300		48
228	Symptoms, ultrasound imaging and biochemical markers alone or in combination for the diagnosis of ovarian cancer in women with symptoms suspicious of ovarian cancer. <i>The Cochrane Library</i> , 2015 , 5, 286-300	5.2	2
227	Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. 2015 , 94, e2402		13
226	Ovary preservation in the treatment of childhood Meigs syndrome. 2015 , 62, 2011-4		3
225	CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. 2015 , 30, e333-40		8
224	Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass. 2015 , 137, 2879-84		7
223	Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases. 2015 , 21, 327-36		8
222	Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. <i>Journal of Gynecologic Oncology</i> , 2015 , 26, 46-53	4	25
221	Postmenopausal Meigs' Syndrome in Elevated CA-125: A Case Report. 2015 , 21, 56-9		8
220	Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. 2015 , 5, 267-76		53
219	Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. <i>PLoS ONE</i> , 2015 , 10, e0121112	3.7	22
218	The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. <i>PLoS ONE</i> , 2015 , 10, e0130197	3.7	19
217	BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer. <i>PLoS ONE</i> , 2015 , 10, e0133081	3.7	14
216	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. 2015 , 137, 430-5		24
215	Comparison of specific ovarian tumor markers by elecsys analyzer 2010. 2015 , 23, 86-9		5
214	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. 2015 , 21, 4960-9		44
213	Cellular leiomyoma with necrosis and mucinous degeneration presenting as pseudo-Meigs' syndrome with elevated CA125. 2015 , 33, 3033-7		10
212	Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. 2015 , 33, 2915-23		113

211	Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. 2015 , 9, 503-12		45
210	Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. 2015 , 36, 1045-53		30
209	Coexistence of benign struma ovarii, pseudo-Meigs' syndrome and elevated serum CA 125: Case report and review of the literature. <i>Oncology Letters</i> , 2015 , 9, 1739-1742	2.6	10
208	Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. 2015 , 107, 322		11
207	Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps. 2015 , 12, 651-67		7
206	Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. 2015 , 115, 10530-74		702
205	Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass. 2015 , 139, 248-52		9
204	Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. 2015 , 14, 4394-401		17
203	ROMA, an algorithm for ovarian cancer. 2015 , 440, 143-51		40
202	Autoantibody signature for the serologic detection of ovarian cancer. 2015 , 14, 578-86		70
201	The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer. 2016 , 30, 709-18		7
200	Refining Ovarian Cancer Test accuracy Scores (ROCKETS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. 2016 , 6, e010333		7
199	High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2016 , 9, 41	5.5	22
198	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. 2016 , 26, 43-51		143
197	The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. 2016 , 11, 125-132		14
196	Protein Z: A putative novel biomarker for early detection of ovarian cancer. 2016 , 138, 2984-92		35
195	[Before surgery predictability of malignant ovarian tumors based on ADNEX model and its use in clinical practice]. 2016 , 44, 557-564		9
194	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. 2016 , 25, 1333-40		31

193	Diagnostik und Management von Adnexraumforderungen. 2016 , 49, 607-622	2
192	The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. 2016 , 5, 41-44	43
191	[Purple-bluish tongue is associated with platelet counts, and the recurrence of epithelial ovarian cancer]. 2016 , 36, 321-5	9
190	Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. 2016 , 127, 848-858	23
189	Differences in the Molecular Species of CA125 Across the Phases of the Menstrual Cycle. 2016 , 18, 23-30	2
188	Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. 2016 , 12, 1	42
187	Respective and simultaneous detection tumor markers CA125 and STIP1 using aptamer-based fluorescent and RLS sensors. 2017 , 245, 470-476	24
186	Assessment of serum HE4 levels throughout the normal menstrual cycle. 2017 , 217, 53.e1-53.e9	4
185	The ascites N-glycome of epithelial ovarian cancer patients. 2017 , 157, 33-39	18
184	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 2017 , 1-27	0
183	MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients: a retrospective clinical study. 2017 , 33, 480-484	6
182	Minimally Invasive Adnexal Mass Extraction: Considerations and Techniques (With Videos). 2017 , 24, 182-188	2
181	Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study. 2017 , 471, 119-125	9
180	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. 2017 , 22, 631-637	60
179	Urinary Polyamines as Biomarkers for Ovarian Cancer. 2017 , 27, 1360-1366	22
178	Screening for Epithelial Ovarian Cancer: An Updated Review. 2017 , 15, 1	0
177	Clinical performance of LOCIbased tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. 2017 , 39, 1010428317730246	13
176	Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. 2017 , 130, e146-e149	26

175	Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. 2017 , 147, 465-480	40
174	Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer. 2017 , 21, 81-87	10
173	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. 2017 , 117, 666-674	29
172	Early screening of ovarian cancer. 2017 , 33, 463-474	2
171	Glycans and glycoproteins as specific biomarkers for cancer. 2017 , 409, 395-410	205
170	ACR Appropriateness Criteria Ovarian Cancer Screening. 2017 , 14, S490-S499	7
169	Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?. 2017 , 32, e83-e89	4
168	A Combinatorial Proteomic Biomarker Assay to Detect Ovarian Cancer in Women.. 2018 , 10, 1179299X18756646	
167	Integrated multiomic predictors for ovarian cancer survival. 2018 , 39, 860-868	4
166	Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer. 2018 , 13, 179-202	4
165	Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. 2018 , 49, 134-139	16
164	Cancer in Pregnancy. 2018 , 353-418.e11	
163	Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. 2018 , 18, 177-186	20
162	The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer. 2018 , 140, 247-252	12
161	Rare Obstructive Müllerian Anomaly with Endometriosis and Elevated CA-125. 2018 , 25, 936-937	
160	Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer. 2018 , 83, 461-465	3
159	Screening for Ovarian Cancer. 2018 ,	
158	Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts. 2018 , 2018, 7821574	2

157	Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. 2018 , 61, 344-351	9
156	Activatable probes for diagnosing and positioning liver injury and metastatic tumors by multispectral optoacoustic tomography. 2018 , 9, 3983	95
155	Elevated CA 125 in a CASE of Leaking Endometrioma. 2018 , 2018, 2385048	3
154	Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment. 2018 , 18, 973	8
153	Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. 2018 , 35,	1
152	Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. 2018 , 24, 39-42	2
151	GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer. 2018 , 18, 328	15
150	Decoding methylation patterns in ovarian cancer using publicly available Next-Gen sequencing data. 2018 , 7, 1	0
149	Relationship Between Serum Tumor-related Markers and Dietary Intakes in Korean Healthy Adults. 2018 , 7, 161-169	2
148	Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal. 2018 , 38, 1140-1145	5
147	Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. 2018 , 221-252	
146	Novel Approaches to Ovarian Cancer Screening. 2019 , 21, 75	19
145	Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. 2019 , 7, 182	30
144	Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma. 2019 , 100, 92-104	7
143	Biomarkers of Gynecological Cancers. 2019 , 133-150	
142	Role of Tumor Markers. 2019 , 233-244	
141	Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study. 2019 , 2, 100012	3
140	Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. 2019 , 56, 527-535	12

139	Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review. 2019 , 28, 109-115		4
138	Sub-terahertz vibrational spectroscopy of ovarian cancer and normal control tissue for molecular diagnostic technology. 2019 , 24, 405-419		3
137	Gynecologic cancers and solid organ transplantation. 2019 , 19, 1266-1277		15
136	Can Presurgical Ultrasound Predict Survival in Women With Ovarian Masses?. 2019 , 35, 39-44		
135	Salivary Biomarkers in Oral Cancer. 2019 , 265-295		4
134	Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management. 2019 , 126, 1255-1265		29
133	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. 2020 , 13, 134		12
132	Biomarkers and Strategies for Early Detection of Ovarian Cancer. 2020 , 29, 2504-2512		22
131	Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer. <i>Scientific Reports</i> , 2020 , 10, 20056	4-9	2
130	Giant abdominal cyst in a young female patient: A case report. 2020 , 72, 549-555		2
129	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. 2020 , 12,		20
128	☒ Grave Illness☒ 2020 , 32, 139-141		
127	Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. 2020 , 13, 241-252		21
126	Label-free electrochemical immunosensor for detection of oncomarker CA125 in serum. 2020 , 155, 104746		24
125	Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. 2020 , 241, 119908		3
124	Ovarian Cancer Targeted Theranostics. 2019 , 9, 1537		12
123	Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. <i>Scientific Reports</i> , 2020 , 10, 2213	4-9	17
122	Improved early detection of ovarian cancer using longitudinal multimarker models. 2020 , 122, 847-856		31

121	A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer. 2020 , 153, 112029		45
120	Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection. 2021 , 81, 39-45		3
119	Evaluation of Biomarkers in Myoma Patients: A Prospective Study Investigating the Role of LDH, CA 125, and IGF-1 after Uterus-Preserving Surgical Therapy. 2021 , 86, 100-107		1
118	Evaluation of Ovarian Cancer Marker HE4 and the Predictive Model of Epithelial Ovarian Cancer ROMA. 2021 , 48,		
117	Pelvic mass, ascites, hydrothorax: a malignant or benign condition? Meigs syndrome with high levels of CA 125. 2021 , 20, 103-107		1
116	The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. 2021 , 42, 327-343		7
115	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. 2021 , 59, 1353-1361	5	
114	Primary Ovarian Mesothelioma: A Case Series with Electron Microscopy Examination and Review of the Literature. <i>Cancers</i> , 2021 , 13,	6.6	2
113	Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode. 2021 , 139, 107742		8
112	Hyperreactio luteinalis after IVF. 2021 , 650-653		
111	Benign, Borderline, and Malignant Pediatric Adnexal Masses: A 10-Year Review. 2021 , 34, 454-461		3
110	Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. <i>Scientific Reports</i> , 2021 , 11, 17308	4.9	2
109	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer. <i>Scientific Reports</i> , 2021 , 11, 18190	4.9	0
108	Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. <i>Diagnostics</i> , 2021 , 11,	3.8	2
107	Postmenopausal Ovarian Cyst. 2021 , 207-222		
106	Ovary. 2002 , 304-320		1
105	Monitoring the Functional Status of the Peritoneum. 2009 , 447-468		2
104	Ovarian Cancer Screening and Early Detection. 2014 , 33-58		2

103	The Ovarian Endometrioma: Clinical Setting and Ultrasound Findings. 2013 , 55-69		1
102	Complementary and coordinate markers for detection of epithelial ovarian cancers. 1995 , 189-192		2
101	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. 2003 , 193-200		1
100	Cancer in Pregnancy. 2007 , 467-531		1
99	Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer. 2018 , 108, 503-514		15
98	SCREENING FOR GYNECOLOGIC CANCER: Vulvar, Vaginal, Endometrial, and Ovarian Neoplasms. <i>Primary Care - Clinics in Office Practice</i> , 1992 , 19, 607-620	2.2	8
97	CANCER SCREENING FOR WOMEN OLDER THAN 40 YEARS OF AGE. <i>Obstetrics and Gynecology Clinics of North America</i> , 1993 , 20, 391-408	3.3	4
96	Inherited Forms of Colorectal, Breast, and Ovarian Cancer: Guidelines for Surveillance. 1994 , 3, 501-521		1
95	Hereditary Ovarian Cancer. 1994 , 3, 523-543		1
94	The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk. 1996 , 39, 860-72		9
93	Early detection and risk reduction for familial gynecologic cancers. 1998 , 41, 200-14		7
92	Screening for ovarian cancer. 1996 , 51, 696-701		7
91	Management of ovarian cysts. 1996 , 313, 1098		12
90	ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. 2020 , 12, 1758835920982853		5
89	CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. 2013 , 19, 230-5		22
88	The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. <i>PLoS Medicine</i> , 2020 , 17, e1003295	11.6	25
87	Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. <i>PLoS ONE</i> , 2014 , 9, e87032	3.7	73
86	Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis. <i>PLoS ONE</i> , 2020 , 15, e0228507	3.7	4

85	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. <i>PLoS ONE</i> , 2020 , 15, e0240418	3.7	4
84	CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. <i>Journal of Clinical and Translational Hepatology</i> , 2018 , 6, 241-246	5.2	8
83	The immune system in the pathogenesis of ovarian cancer. <i>Critical Reviews in Immunology</i> , 2013 , 33, 137-164	4.1	41
82	with Pseudo-Meigs' Syndrome and Raised Cancer Antigen-125 Levels Masquerading as an Ovarian Carcinoma Case report and literature review. <i>Sultan Qaboos University Medical Journal</i> , 2017 , 17, e229-e233	0.9	5
81	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 785-797	3.3	10
80	Parentlitic networks for predicting ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 22717-22726	3.3	19
79	The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e83	4	4
78	Identification and validation of core genes for serous ovarian adenocarcinoma via bioinformatics analysis. <i>Oncology Letters</i> , 2020 , 20, 145	2.6	4
77	Role of Frozen Section in Surgical Management of Ovarian Neoplasm. <i>Gynecology and Minimally Invasive Therapy</i> , 2020 , 9, 13-17	1.1	2
76	The Value of Tumor Markers in Endometrial Carcinoma: Review of Literature. <i>Journal of Cancer Therapy</i> , 2013 , 04, 966-970	0.2	6
75	Proteomic approaches to tumor marker discovery. <i>Archives of Pathology and Laboratory Medicine</i> , 2002 , 126, 1518-26	5	181
74	Serum CA-125 for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2021 , 21, 1091	4	2
73	Serum CA 125 and fallopian tube carcinoma. <i>Annals of Saudi Medicine</i> , 2001 , 21, 130	1.6	
72	Early Diagnosis and Screening for Ovarian Cancer. 2003 , 219-229		
71	Malignes Wachstum. 2005 , 425-465		
70	Ovarian Cancer. 2007 , 195-214		
69	Malignes Wachstum. 2009 , 465-502		0
68	Ovarian Cancer Screening. 2010 , 87-107		

- 67 Adnexal Masses. 271-274
- 66 Gynaecology. **2011**, 728-759
- 65 Diagnosis and Management of Cancer Using Serologic and Tissue Tumor Markers. **2011**, 1385-1399
- 64 Tumor Markers. **2012**, 617-667 1
- 63 Hyperreactio Luteinalis after IVF. 409-411
- 62 Cancer Antigen-125 is Specifically Associated with Ascites and has no Relation with Liver Function in Liver Cirrhosis. *Euroasian Journal of Hepato-gastroenterology*, **2013**, 3, 108-110 1.6
- 61 Development and evaluation of an ELISA method for the measurement of kallikrein-related peptidase 5 (KLK5) in human serum. *Open Journal of Clinical Diagnostics*, **2013**, 03, 159-166 0.2 1
- 60 Neoadjuvant chemotherapy and cytoreductive surgery in epithelial ovarian cancer. *World Journal of Obstetrics and Gynecology*, **2013**, 2, 153 0.1
- 59 CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL. *Journal of Evolution of Medical and Dental Sciences*, **2013**, 2, 4778-4782 0.1
- 58 Diagnosis and Management of Epithelial Ovarian Cancer with Peritoneal Metastases. **2014**, 185-198
- 57 MUC16, alias CA125 and ovarian cancer. **2013**, 82-93
- 56 Role of minimally invasive surgery in complex adnexal tumours and ovarian cancer. *World Journal of Obstetrics and Gynecology*, **2014**, 3, 109 0.1
- 55 TUMOR MARKERS. *Primary Care - Clinics in Office Practice*, **1992**, 19, 715-726 2.2 2
- 54 Screening for Ovarian Cancer. **1993**, 141-152
- 53 Screening for ovarian cancer: Authors' reply. **1993**, 306, 1685-1685
- 52 LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS. *Obstetrics and Gynecology Clinics of North America*, **1994**, 21, 79-92 3.3 14
- 51 Screening for Ovarian Cancer. *Focus on Cancer*, **1996**, 95-115
- 50 PET Imaging in Oncology. **1999**, 313-331

49	Laparoscopic Ovarian Cystectomy. 2016 , 1-12		
48	Applications of Non-coding RNA in the Molecular Pathology of Cancer. 2016 , 177-217		
47	Screening and Prevention of Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017 , 57-81		0
46	Laparoscopic Ovarian Cystectomy. 2017 , 629-640		
45	THE RELATION BETWEEN CA 125, CECT ABDOMEN & PELVIS AND HISTOPATHOLOGICAL FEATURES IN OVARIAN NEOPLASMS. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2019 , 8, 186-190	0.1	
44	Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Tests in Ovarian Cancer. <i>International Journal of Cancer Management</i> , 2019 , In Press,		0.9
43	Production and Performance Evaluation of External Quality Assessment Materials for Human Epididymis Protein 4 Assay. <i>Journal of Laboratory Medicine and Quality Assurance</i> , 2019 , 41, 153-160		0.6
42	Evaluation of the Diagnostic Potential of Candidate Hypermethylated Genes in Epithelial Ovarian Cancer in North Indian Population. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 719056	5.6	0
41	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
40	Monitoring the Functional Status of the Peritoneum. 2021 , 1-31		
39	Endometriosis: A Malignant Fingerprint. 2020 , 8,		1
38	ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
37	PET and PET/CT Imaging in Testicular and Gynecologic Cancers. 2006 , 217-231		
36	Cancer ovarien. 2005 , 407-420		
35	Molecular Markers in Epithelial Ovarian Cancer. 2007 , 29-47		
34	Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. <i>World Journal of Clinical Oncology</i> , 2020 , 11, 868-889	2.5	3
33	Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. <i>Transactions of the American Clinical and Climatological Association</i> , 2004 , 115, 233-47; discussion 247-8	0.9	26
32	Ovarian cancer screening and early detection in the general population. <i>Reviews in Obstetrics and Gynecology</i> , 2011 , 4, 15-21		75

31	Meigs' syndrome with elevated serum CA125 in a case of ovarian fibroma /thecoma. <i>Caspian Journal of Internal Medicine</i> , 2014 , 5, 43-5	1	5
30	CA-125 variation in acute heart failure: a single-centre analysis.. <i>ESC Heart Failure</i> , 2022 ,	3.7	2
29	Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
28	Low-Grade Serous Carcinoma of the Ovary: The Current Status.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
27	Radiomics analysis based on CT's greater omental caking for predicting pathological grading of pseudomyxoma peritonei.. <i>Scientific Reports</i> , 2022 , 12, 4401	4.9	0
26	Tratamiento de las masas anexiales durante el embarazo. <i>EMC - Ginecología-Obstetricia</i> , 2022 , 58, 1-12	0	
25	Relationship between Serum Tumor-Related Markers and Genetically Modified Rice Expressing Cry1Ab Protein in Sprague-Dawley Rats. <i>Nutrition and Cancer</i> , 2021 , 1-10	2.8	
24	The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.. <i>Journal of Ovarian Research</i> , 2021 , 14, 179	5.5	0
23	Data_Sheet_1.PDF. 2019 ,		
22	A new algorithm to assess the risk of malignancy in premenopausal patients with pelvic mass. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2022 , 18, 76-86	0.3	
21	The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets.. <i>Cancers</i> , 2022 , 14,	6.6	
20	BRAK and APRIL as novel biomarkers for ovarian tumors.. <i>Biomarkers in Medicine</i> , 2022 ,	2.3	
19	Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. <i>Cancers</i> , 2022 , 14, 2885	6.6	2
18	The Role of Three Plasma Proteins in the Diagnosis of Ovarian Tumors. <i>Journal of Biomedical and Clinical Research</i> , 2022 , 15, 41-46	0	
17	Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	0
16	Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. 9,		1
15	Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women. 2022 , 19, 9896		0
14	A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. OF1-OF8		0

- 13 Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer. **2022**, ○
- 12 Ovarian Cancer Screening and Early Detection. **2022**, 9-25 ○
- 11 Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 1-23 ○
- 10 Cancer in pregnancy. **2023**, 345-414.e10 ○
- 9 Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages. **2022**, 14, 5867 ○
- 8 Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses. **2023**, 15, 667 ○
- 7 Monitoring the Functional Status of the Peritoneum. **2023**, 361-391 ○
- 6 High-sensitivity profiling of glycoproteins from ovarian cancer sera using lectin-affinity and LC-ESI-Q-TOF-MS/MS. **2023**, 5, 100122 ○
- 5 Epithelial Ovarian Cancer. **2022**, 291-323 ○
- 4 Osteopontin as a tumor marker in ovarian cancer. **2022**, 13, 200 ○
- 3 Exosomes as crucial emerging tools for intercellular communication with therapeutic potential in ovarian cancer. **2023**, 9, ○
- 2 Chistadenom mucinos gigant recidivat în az clinic. **2023**, 1, 44 ○
- 1 Diagnostic and prognostic value of circulating tumor cells in Indian women with suspected ovarian cancer. **2023**, 19, 268 ○